Dehradun, August 20, 2026: Doctors at Max Super Speciality Hospital, Saket, have successfully treated a 65-year-old patient suffering from relapsed Diffuse Large B-Cell Lymphoma (DLBCL), an aggressive form of blood cancer, using advanced CAR-T cell therapy.
The case highlights the growing role of cellular therapies in treating patients whose blood cancer returns despite conventional chemotherapy, while also underlining the importance of specialised haematology, bone marrow transplantation and cellular therapy expertise.
Mr. Sharad Chandra Jhaldiyal, a resident of Dehradun, was diagnosed with DLBCL in 2020. He underwent six cycles of R-CHOP chemotherapy in Mumbai. However, the disease subsequently relapsed. Following the recurrence of lymphoma, he was evaluated for CAR-T cell therapy and admitted to Max Super Speciality Hospital, Saket, for advanced treatment.
Before receiving CAR-T cell therapy, the patient underwent the required preparatory chemotherapy. CAR-T therapy is an advanced cellular treatment in which a patient’s own immune cells are genetically modified so that they can better recognise and attack cancer cells.
The patient was treated under the care of a multidisciplinary team comprising specialists in haemato-oncology, bone marrow transplantation and cellular therapy. After approximately one month of hospitalisation, he was discharged and is currently doing well.
According to the hospital, the patient currently has no signs or symptoms of cancer and his disease remains under control.
Speaking about the case, Dr. Rayaz Ahmed, Vice Chairman, Department of Haematology and Bone Marrow Transplantation, Max Super Speciality Hospital, Saket, said that relapsed DLBCL can be challenging to treat, particularly when the disease returns after conventional chemotherapy.
He said CAR-T cell therapy has emerged as an important treatment option for carefully selected patients with relapsed disease. The therapy involves re-engineering the patient’s own immune cells to enable them to recognise and target cancer cells more effectively.
Dr. Ahmed further emphasised that CAR-T therapy requires specialised infrastructure, an experienced medical team and close monitoring before, during and after treatment. He said that appropriate patient selection and multidisciplinary management played an important role in completing the treatment safely in this case.
“Cellular therapy represents an important advancement in the treatment of relapsed or refractory blood cancers,” Dr. Ahmed said, adding that successful treatment depends not only on the availability of the therapy but also on comprehensive patient evaluation, cellular therapy protocols, specialised nursing, laboratory monitoring, critical-care support and coordinated management of potential complications.
The successful treatment offers renewed hope to patients with aggressive blood cancers who experience relapse following conventional treatment and demonstrates the potential of advanced cellular therapies in managing complex cases of blood cancer.
